Ashley Preston

Ashley Preston is an accomplished professional in the field of Global Regulatory Affairs and Quality Assurance, currently serving as SVP at BlossomHill Therapeutics, Inc. since January 2025. Previously, Ashley held the position of SVP at Syros Pharmaceuticals, where responsibilities included building the regulatory organization and executing global regulatory strategies across multiple clinical-stage assets. Prior roles at H3 Biomedicine, EMD Serono, and Merck involved establishing regulatory functions and engaging with regulatory agencies on international policy matters. Ashley's extensive experience also includes leadership roles at Takeda and Avexa Limited, focusing on regulatory strategy and submissions across various therapeutic areas. Educational qualifications include a PhD in Pharmacology from RMIT University and a BSc (Honours) from Monash University.